Savara (NSDQ:SVRA) announced today that it closed its previously announced public offering with proceeds reaching approximately $130 million. Austin, Texas-based Savara last week announced the offering of 45.8 million shares of its common stock to the public for $1.45 per share, expecting proceeds of $113 million. However, the company today said in a news release […]
Savara Inc.
Savara prices $113M offering
Savara (NSDQ:SVRA) announced today that it priced an underwritten public offering of common stock at approximately $113 million. Austin, Texas-based Savara — an orphan lung disease treatment company with an inhaled formulation of recombinant human GM-CSF — is offering nearly 45.8 million shares of its common stock to the public for $1.45 per share, according to […]
Savara inks $15m loan agreement
Savara (NSDQ:SVRA) said today that it inked a $15 million loan agreement with Silicon Valley Bank. According to the deal, Savara can draw $7.5 million from the $15 million debt facility immediately. The company said it plans to use its newly-acquired capital to repay the pre-merger debt of $3.7 million it owes to Hercules Technology […]
Mast Therapeutics, Savara ink merger deal
Mast Therapeutics (NYSE:MSTX) and privately-held Savara Inc. said today that the 2 companies have landed a definitive merger agreement, combining their operations. The newly-formed Austin, Texas-based company is expected to be named Savara Inc., and trade on the NYSE market under a new ticker symbol. The combined company will focus on advancing a pipeline of […]
